- Home
- ACI vs INCY Comparison
ACI vs INCY Comparison
Compare ACI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACI
- INCY
- Stock Information
- Founded
- ACI 1860
- INCY 1991
- Country
- ACI United States
- INCY United States
- Employees
- ACI N/A
- INCY N/A
- Industry
- ACI Food Chains
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ACI Consumer Staples
- INCY Health Care
- Exchange
- ACI Nasdaq
- INCY Nasdaq
- Market Cap
- ACI 12.7B
- INCY 13.4B
- IPO Year
- ACI 2020
- INCY 1993
- Fundamental
- Price
- ACI $21.90
- INCY $59.16
- Analyst Decision
- ACI Buy
- INCY Hold
- Analyst Count
- ACI 11
- INCY 20
- Target Price
- ACI $23.27
- INCY $73.81
- AVG Volume (30 Days)
- ACI 7.3M
- INCY 2.0M
- Earning Date
- ACI 04-15-2025
- INCY 04-29-2025
- Dividend Yield
- ACI 2.74%
- INCY N/A
- EPS Growth
- ACI N/A
- INCY N/A
- EPS
- ACI 1.64
- INCY 0.15
- Revenue
- ACI $80,390,900,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- ACI $4.69
- INCY $12.21
- Revenue Next Year
- ACI $0.58
- INCY $9.20
- P/E Ratio
- ACI $13.36
- INCY $392.73
- Revenue Growth
- ACI 1.46
- INCY 14.76
- 52 Week Low
- ACI $17.00
- INCY $50.35
- 52 Week High
- ACI $23.20
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ACI 52.60
- INCY 46.02
- Support Level
- ACI $19.63
- INCY $57.29
- Resistance Level
- ACI $22.69
- INCY $59.95
- Average True Range (ATR)
- ACI 0.78
- INCY 2.57
- MACD
- ACI 0.07
- INCY 0.44
- Stochastic Oscillator
- ACI 74.18
- INCY 70.80
About ACI Albertsons Companies Inc.
Albertsons is the second largest supermarket operator in the United States with more than 2,200 stores across a variety of banners. About 80% of the firm's sales stem from non-perishable and fresh food, of which 25% comes from its portfolio of private brands. The company operates fuel centers and pharmacies at about 20% and 75% of its store locations, respectively. Albertsons went public in 2020 following years of ownership under private equity firm Cerberus Capital Management, which still owns about a fourth of outstanding shares.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.